ALT5 Sigma Corp is a U.S.-based holding company whose continuing operations are concentrated in a Fintech segment built around the acquired ALT5 Subsidiary (May 2024) and the acquired Mswipe business (May 2025). The company generates revenue from fintech-related products and services (reported as 100% of net revenue in the cited quarters), while its Biotechnology activities have been presented as discontinued operations following a formal separation process disclosed in 2025. Recent performance commentary attributes most revenue and gross profit growth to acquisition-driven expansion rather than organic growth alone. The business profile is therefore shaped by integration execution, scaling transaction-driven fintech revenues, and funding needs alongside corporate overhead and legacy biotech-related items.
15
0.57
0.17
| % | |
|---|---|
| Fintech (ALT5 Subsidiary) | 75% Fintech products and services delivered through the ALT5 Subsidiary acquired in May 2024. |
| Fintech (Mswipe) | 25% Payment/fintech services and related revenues from Mswipe acquired in May 2025. |
| Biotechnology (discontinued operations) | 0% Biotech assets and development programs (e.g., Alyea/JAN 123) presented as discontinued operations. |
| Corporate & Other | 0% Public company costs, legal/professional services, and shared overhead not directly generating revenue. |
Based on segment disclosures, ALT5 Sigma’s external revenue is generated entirely by its Fintech segment, implying...
Use payment/fintech services (including Mswipe) to accept and manage digital payments and related workflows.
Adopt ALT5 Subsidiary fintech services for higher-volume processing and integration into business systems.
Drive transaction volumes through partnerships, integrations, or referral/channel distribution arrangements.
The provided excerpts do not include an authoritative revenue-by-geography table or country-level revenue disclosure,...
Management commentary emphasizes improving overall profitability by managing expenses in a challenging competitive...
Recent revenue growth is attributed to acquisitions, so execution drives run-rate and margins.
SG&A increased materially alongside acquisitions; controlling overhead affects operating leverage.
Company disclosed formal separation steps and potential subsidiary financing to fund development while reducing entanglement with core operations.
A primary company-specific risk is execution risk from acquisition-driven growth: revenue and gross profit increases...
Management disclosed dependence on future capital raises/structured arrangements and noted negative working capital, increasing the risk of dilution or constrained operations.
Revenue and cost changes were attributed to acquisitions; failure to integrate could sustain elevated SG&A and reduce gross profit percentage.
The company referenced an SEC Complaint and added supplemental risk factors, which can lead to legal costs, operational constraints, or reputational harm.
BHIC · Services-Computer Processing & Data Preparation
RIME · Services-Computer Integrated Systems Design
ASBP · Pharmaceutical Preparations
PHGE · Biological Products, (No Diagnostic Substances)
MIRA · Pharmaceutical Preparations
CTMX · Pharmaceutical Preparations
CytomX Therapeutics is a clinical-stage biopharmaceutical company built around its PROBODY platform, which masks biologic drug activity until it reaches the tumor microenvironment.
: 11/08/2026